mineralocorticoid receptor
Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis
... nonsteroidal mineralocorticoid receptor antagonists may carry a re- duced risk of side-effects, and these agents have shown promise for reduction of albuminuria in diabetic CKD ...
14
Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice
... a mineralocorticoid receptor (MR) agonist, is associated with increased inflammation and risk of cardiovascular ...glucocorticoid receptor) to enhance alternative ...
16
Two Mineralocorticoid Receptor–Mediated Mechanisms of Pendrin Activation in Distal Nephrons
... of mineralocorticoid receptor in intercalated cells suppressed the increase in renal pendrin expression induced by either exogenous angiotensin II infusion or endogenous angiotensin II upregulation via salt ...
16
Review Article Clinical effect of mineralocorticoid receptor antagonist combined with angiotensin receptor blocker or angiotensin converting enzyme inhibitor in treating diabetic nephropathy: a systematic review and meta-analysis
... especially in DN patients [6]. However, despite RAS blockade by ARBs/ACEIs, a relatively high- level of albuminuria remains in DN patients re- ceiving this treatment, and progression to ES- RD can occur [7, 8]. This ...
14
Vascular mineralocorticoid receptor regulates microRNA-155 to promote vasoconstriction and rising blood pressure with aging
... Cell Mineralocorticoid Receptor in Vascular ...which mineralocorticoid receptor (MR) expression rises in aging resistance vessel smooth muscle cells where MR suppresses miR-155 transcription ...
18
Original Article The selective mineralocorticoid receptor antagonist eplerenone is protective in mild anti-GBM glomeru- lonephritis
... tensin receptor blockers (ARB) was shown to successfully delay the progression of renal dis- ease ...that mineralocorticoid receptor antagonists may re- duce proteinuria and attenuate renal injury ...
10
Mineralocorticoid receptor activation and blockade: an emerging paradigm in chronic kidney disease
... mineralocorticoid receptor (MR) expression and activation (either dependent on aldosterone or direct ligand- independent activation) and its blockade have been illustrated with ex vivo in cell cultures and ...
10
Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials
... MRAs: Mineralocorticoid receptor antagonists; PEF: Preserved ejection fraction; PIIINP: Peptide of procollagen type-III; QoL: Quality of life; RCTs: Randomized controlled trials; RD: Risk reduction; RR: ...
12
Pharmacological Profile of KBP-5074, a Novel Non-Steroidal Mineralocorticoid Receptor Antagonist for the Treatment of Cardiorenal Diseases
... Aldosterone is a steroid hormone produced primarily in the glomerular zone of the adrenal cortex. It has been implicated for many years to play an important role in the pathophysiology of cardiovascular and renal ...
9
Sex-specific responses to mineralocorticoid receptor antagonism in hypertensive African American males and females
... Mineralocorticoid receptor antagonists, the primary derivatives being spironolactone and eplerenone, are used to treat hypokalemia, heart failure, acne, and poly- cystic ovary syndrome in addition to ...
7
Patient characteristics and initiation of mineralocorticoid receptor antagonists in patients with chronic kidney disease in routine clinical practice in the US: a retrospective cohort study
... the mineralocorticoid receptor present in both cardiac and renal cells in response to elevated al- dosterone levels, high salt load, increased plasma glucose or increased reactive oxygen species generation ...
14
Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial.
... Clinical Investigation Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE [r] ...
9
Mineralocorticoid receptor antagonists in dialysis patients
... [2]. Mineralocorticoid receptor (MR) antagonists have been reported to improve the prognosis of chronic heart failure [3, 4], heart failure after acute myocardial infarction [5], and left ventricular (LV) ...
9
Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE STEMI trial
... Clinical Investigations Mineralocorticoid receptor antagonist pre-treatment and early post-treatment to minimize reperfusion injury after ST-elevation myocardial infarction: The MINIMIZE[r] ...
8
Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
... potent mineralocorticoid receptor (MR) antagonist with undesirable side effects; it was followed a decade ago by eplerenone, which is less potent but much more ...
10
Mineralocorticoid receptor antagonist pretreatment to MINIMISE reperfusion injury after ST-elevation myocardial infarction (the MINIMISE STEMI Trial): rationale and study design.
... MRA, mineralocorticoid receptor antagonist; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery; SBP, systolic blood pressure; sCr, serum creatinine; STEMI, ST-elevation myocardial ...
9
A Cardiac Mouse Model for Nongenomic Mineralocorticoid Receptor Effects
... The mineralocorticoid receptor (MR) is a steroid hormone receptor and therefore a member of the nuclear receptor subfamily [1]. The MR takes part in blood pressure regulation by controlling ...
13
Antihypertensive effect of the mineralocorticoid receptor antagonist eplerenone: a pooled analysis of patient-level data from comparative trials using regulatory-approved doses
... selective mineralocorticoid receptor blockade with eplerenone can be safely used and is an effective therapeutic option for patients with hypertension, which may be of particular importance in those ...
14
Long term antidepressant administration alters corticotropin releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain Therapeutic implications
... hippocampal mineralocorticoid receptor (MR, type I) that is thought to play an important role in mediating the negative feedback effects of low levels of steroids on the hypothalamic-pituitary-adrenal (HPA) ...
8
Mineralocorticoid receptor is involved in rat and human ocular chorioretinopathy
... Central serous chorioretinopathy (CSCR) is a vision-threatening eye disease with no validated treatment and unknown pathogeny. In CSCR, dilation and leakage of choroid vessels underneath the retina cause subreti- nal ...
9